Today's Dead Cat Bounce Stock: Halozyme Therapeutics (HALO)

Trade-Ideas LLC identified Halozyme Therapeutics ( HALO) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Halozyme Therapeutics as such a stock due to the following factors:

  • HALO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $14.2 million.
  • HALO has traded 295,681 shares today.
  • HALO is up 3.4% today.
  • HALO was down 6.1% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in HALO with the Ticky from Trade-Ideas. See the FREE profile for HALO NOW at Trade-Ideas

More details on HALO:

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Currently there are 4 analysts that rate Halozyme Therapeutics a buy, 1 analyst rates it a sell, and none rate it a hold.

The average volume for Halozyme Therapeutics has been 1.6 million shares per day over the past 30 days. Halozyme has a market cap of $1.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.81 and a short float of 21.3% with 12.64 days to cover. Shares are down 50.8% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Halozyme Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally high debt management risk, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

If you liked this article you might like

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

Good Stocks Are There for the Picking

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme